This study provides evidence that the combination of targeted drug delivery of an inhibitory biopolymer (Bac-ELP1-H1) with systemic chemotherapy (TMZ) can lead to a synergistic effect that enhances the efficacy of glioblastoma treatment and improves patient survival. The gene discussed is ELP1; the disease is glioblastoma.